LAB
Standard Biotools Inc
Standard Biotools Inc historical holders
total: 2
Viking Global Investors Standard Biotools Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2024 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2024 Q1
Ole Andreas Halvorsen has been an institutional investor in Standard Biotools Inc (LAB) since 2024 Q1. According to 2026 Q1 report, Ole Andreas Halvorsen holds 58,651,170 shares with a market value of roughly $53.92M representing 0.15% of their equity portfolio. The fund/company first acquired LAB in 2024 Q1, initially purchasing about 58.65M shares.
Does Ole Andreas Halvorsen still hold LAB?
Yes, Ole Andreas Halvorsen continues to hold Standard Biotools Inc (LAB). According to their 2026 Q1 report, they maintain a position of 58,651,170 shares valued at approximately $53.92M, representing 0.15% of their equity portfolio.
When did Ole Andreas Halvorsen first invest in LAB?
Ole Andreas Halvorsen first invested in Standard Biotools Inc (LAB) in 2024 Q1 at the reported quarter-end price of $2.71 per share, acquiring 58,651,170 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for LAB?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Standard Biotools Inc (LAB) is approximately $2.71 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $2.71
LAB transactions history by Viking Global Investors
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q1
|
0.59%
|
58,651,170
|
$2.71
|
$158,944,671
|
new
|
+0.59%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.